Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination - PubMed (original) (raw)
Review
Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination
Mathias Vormehr et al. J Immunol Res. 2015.
Abstract
Advances in nucleic acid sequencing technologies have revolutionized the field of genomics, allowing the efficient targeting of mutated neoantigens for personalized cancer vaccination. Due to their absence during negative selection of T cells and their lack of expression in healthy tissue, tumor mutations are considered as optimal targets for cancer immunotherapy. Preclinical and early clinical data suggest that synthetic mRNA can serve as potent drug format allowing the cost efficient production of highly efficient vaccines in a timely manner. In this review, we describe a process, which integrates next generation sequencing based cancer mutanome mapping, in silico target selection and prioritization approaches, and mRNA vaccine manufacturing and delivery into a process we refer to as MERIT (mutanome engineered RNA immunotherapy).
Figures
Figure 1
Concept of mutanome engineered RNA immunotherapy (MERIT). Next generation sequencing of nucleic acid from a tumor biopsy and healthy tissue is used to identify expressed, nonsynonymous, somatic mutations. Vaccine targets are selected based on several parameters such as expression, their MHC binding prediction, and restriction as well as a false discovery rate (FDR) [16]. Mutations encoded on pentatope RNAs are produced under GMP conditions and used for therapeutic vaccination.
Figure 2
Structure of the pentatope RNA vaccine. Several modifications in the 5′ cap, 5′ and 3′ untranslated regions (UTR), poly(A) tail, and codon usage increased the translation efficiency and stability of the mRNA [30, 31]. Mutated sequences (Mut1–5) encoding 27 amino acids with the mutation in the center (red letter) are separated by nonimmunogenic 10 mer linkers. The antigen encoding sequences are flanked by a signal peptide and the MHC class I trafficking domain (MITD, transmembrane, and cytoplasmic domain of MHC class I) to ensure optimal antigen presentation [32].
Similar articles
- Personalized cancer vaccines: Targeting the cancer mutanome.
Zhang X, Sharma PK, Peter Goedegebuure S, Gillanders WE. Zhang X, et al. Vaccine. 2017 Feb 15;35(7):1094-1100. doi: 10.1016/j.vaccine.2016.05.073. Epub 2016 Jul 20. Vaccine. 2017. PMID: 27449681 Free PMC article. Review. - Cancer Neoantigens and Applications for Immunotherapy.
Desrichard A, Snyder A, Chan TA. Desrichard A, et al. Clin Cancer Res. 2016 Feb 15;22(4):807-12. doi: 10.1158/1078-0432.CCR-14-3175. Epub 2015 Oct 29. Clin Cancer Res. 2016. PMID: 26515495 Review. - Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines.
Türeci Ö, Vormehr M, Diken M, Kreiter S, Huber C, Sahin U. Türeci Ö, et al. Clin Cancer Res. 2016 Apr 15;22(8):1885-96. doi: 10.1158/1078-0432.CCR-15-1509. Clin Cancer Res. 2016. PMID: 27084742 Review. - Neoantigen vaccine: an emerging tumor immunotherapy.
Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, Guo C, Wu X, Li Y, Li X, Li G, Xiong W, Zeng Z. Peng M, et al. Mol Cancer. 2019 Aug 23;18(1):128. doi: 10.1186/s12943-019-1055-6. Mol Cancer. 2019. PMID: 31443694 Free PMC article. Review. - Applications of Next-Generation Sequencing in Neoantigen Prediction and Cancer Vaccine Development.
Lancaster EM, Jablons D, Kratz JR. Lancaster EM, et al. Genet Test Mol Biomarkers. 2020 Feb;24(2):59-66. doi: 10.1089/gtmb.2018.0211. Epub 2019 Mar 22. Genet Test Mol Biomarkers. 2020. PMID: 30907630 Review.
Cited by
- Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities.
Wang B, Pei J, Xu S, Liu J, Yu J. Wang B, et al. Front Immunol. 2023 Sep 6;14:1246682. doi: 10.3389/fimmu.2023.1246682. eCollection 2023. Front Immunol. 2023. PMID: 37744371 Free PMC article. Review. - Computational and Experimental Evaluation of the Immune Response of Neoantigens for Personalized Vaccine Design.
Malaina I, Gonzalez-Melero L, Martínez L, Salvador A, Sanchez-Diez A, Asumendi A, Margareto J, Carrasco-Pujante J, Legarreta L, García MA, Pérez-Pinilla MB, Izu R, Martínez de la Fuente I, Igartua M, Alonso S, Hernandez RM, Boyano MD. Malaina I, et al. Int J Mol Sci. 2023 May 19;24(10):9024. doi: 10.3390/ijms24109024. Int J Mol Sci. 2023. PMID: 37240369 Free PMC article. - mRNA vaccination in breast cancer: current progress and future direction.
Jiang XT, Liu Q. Jiang XT, et al. J Cancer Res Clin Oncol. 2023 Sep;149(11):9435-9450. doi: 10.1007/s00432-023-04805-z. Epub 2023 Apr 26. J Cancer Res Clin Oncol. 2023. PMID: 37100972 Free PMC article. Review. - Nanotechnology-Based Nucleic Acid Vaccines for Treatment of Ovarian Cancer.
Gildiz S, Minko T. Gildiz S, et al. Pharm Res. 2023 Jan;40(1):123-144. doi: 10.1007/s11095-022-03434-4. Epub 2022 Nov 14. Pharm Res. 2023. PMID: 36376606 Free PMC article. Review. - mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model.
Sittplangkoon C, Alameh MG, Weissman D, Lin PJC, Tam YK, Prompetchara E, Palaga T. Sittplangkoon C, et al. Front Immunol. 2022 Oct 14;13:983000. doi: 10.3389/fimmu.2022.983000. eCollection 2022. Front Immunol. 2022. PMID: 36311701 Free PMC article.
References
- NHGRI. Human Genome Project Completion: Frequently Asked Questions, 2010, http://www.genome.gov/11006943.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources